Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine how effective and safe a new investigational drug
is in treating persistent or recurrent ovarian cancer in patients who have received a
platinum/taxane based chemotherapy and whose disease continues to progress. The treatment
involves a 1-hour treatment given intravenously (IV), and repeated once every 21 days. A
patient may continue to receive the treatment as long as they are benefiting from the
treatment. Blood samples will be taken at specific times over a 24 hour period to measure the
amount of drug in your body at specific times after the drug is given. Blood samples will
also be taken for routine lab tests such as complete blood counts and clinical chemistries.
Physical exams will be performed before each treatment.